Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of
molecular alterations, and as such, long-term disease control requires multiple therapeutic …

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown
unprecedented clinical activity in several types of cancer and are rapidly transforming the …

The past decade has seen the emergence of immunotherapy as a prime approach to cancer
treatment, revolutionizing the management of many types of cancer. Despite the promise of …

Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

Although cancer immunotherapy has taken center stage in mainstream oncology inducing
complete and long-lasting tumor regression, only a subset of patients receiving treatment …

Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized
the treatment of a wide variety of malignancies, leading to durable therapeutic responses not …

Pancreatic ductal adenocarcinoma (PDAC) belongs to the most lethal solid tumors in
humans. A histological hallmark feature of PDAC is the pronounced tumor microenvironment …

Cancer immunotherapies that harness the body's immune system to combat tumors have
received extensive attention and become mainstream strategies for treating cancer. Despite …

Interactions between immune checkpoints (ICs) and their ligands negatively regulate T cell
activation pathways involved in physiological immune responses against specific antigens …